

Appendix: Tables

1.	Sales January to September 2024 and 2023	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2024 and 2023	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD September 2024 vs. YTD September 2023	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	10

1. Sales January to September 2024 and 2023

CHF millions	Nine months ended 30 September		% change	
	2024	2023	At CER	In CHF
Pharmaceuticals Division	34,257	33,372	7	3
United States	18,166	17,430	7	4
Europe	6,613	6,259	7	6
Japan	2,083	2,937	-21	-29
International*	7,395	6,746	19	10
Diagnostics Division	10,727	10,681	5	0
Roche Group	44,984	44,053	6	2

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

All figures shown in the table were restated to reflect the shift of the FMI business from Pharma Division to Diagnostics Division

2. Quarterly sales and constant exchange rate sales growth by Division in 2024 and 2023

CHF millions	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023
Pharmaceuticals Div.	10,861	11	10,893	-2	10,921	2	11,716	9	11,620	10
United States	5,857	11	5,829	5	5,692	5	6,190	6	6,284	9
Europe	2,154	9	2,047	3	2,200	11	2,225	10	2,188	2
Japan	727	1	808	-50	649	-45	717	-3	717	1
International*	2,123	17	2,209	16	2,380	12	2,584	23	2,431	22
Diagnostics Division	3,413	-5	3,770	4	3,478	2	3,733	8	3,516	6
Roche Group	14,274	7	14,663	0	14,399	2	15,449	9	15,136	9

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

All figures shown in the table were restated to reflect the shift of the FMI business from Pharma Division to Diagnostics Division

3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD September 2024 vs. YTD September 2023

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	5,056	9	3,640	7	961	11	-	-	455	26
Hemlibra	3,280	10	1,906	5	690	10	259	4	425	42
Vabysmo	2,816	79	2,146	67	454	148	86	37	130	256
Perjeta	2,809	-1	1,029	-4	502	-17	92	-36	1,186	17
Tecentriq	2,703	1	1,325	-8	649	5	277	-1	452	32
Actemra/RoActemra	1,948	5	949	11	508	-11	225	9	266	17
Xolair	1,737	11	1,737	11	-	-	-	-	-	-
Kadcyla	1,494	6	574	4	428	-2	71	4	421	22
Evrysdi	1,246	21	429	15	435	18	66	10	316	35
Phesgo	1,244	58	404	29	543	44	88	-	209	104
Alecensa	1,151	7	372	12	217	1	144	3	418	8
Herceptin	1,063	-11	201	-20	227	-15	11	-48	624	-5
MabThera/Rituxan	1,023	-16	615	-17	109	-21	12	-26	287	-10
Avastin	943	-17	289	-20	63	-17	149	-33	442	-8
Activase/TNKase	895	2	850	1	-	-	-	-	45	5
Polivy	817	41	410	83	142	6	143	-4	122	79
Gazyva	670	13	333	15	185	8	21	-16	131	21
Pulmozyme	329	0	213	-5	55	-3	1	17	60	23
Mircera	304	-1	-	-	31	-6	28	-23	245	4
CellCept	283	1	17	-21	81	-13	27	-9	158	17
Enspryng	223	29	65	30	22	76	105	7	31	213
Elevidys	137	-	-	-	-	-	-	-	137	-
Columvi	116	**	66	**	27	**	-	-	23	**

Xofluza	99	223	5	82	-	-	-	-	94	237
Rozlytrek	98	61	38	16	16	33	6	19	38	237
Lunsumio	54	28	41	11	13	132	-	-	-	152
Cotellic	30	-21	12	-29	8	-1	-	-	10	-23
Luxturna	15	-65	15	-65	-	-	-	-	-	-
Piasky	8	-	-	-	-	-	8	-	-	-
Ronapreve	3	-99	-	-	3	**	-	-100	-	-99
Susvimo	3	18	3	18	-	-	-	-	-	-
Pharma other	1,660	-24	482	-44	244	-13	264	-20	670	-7
Pharma total sales	34,257	7	18,166	7	6,613	7	2,083	-21	7,395	19

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

** Over 500%

4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023
Ocrevus	1,567	12	1,614	9	1,658	8	1,701	9	1,697	11
Hemlibra	1,025	17	1,035	9	1,040	8	1,103	6	1,137	14
Vabysmo	656	309	744	160	847	108	947	81	1,022	59
Perjeta	913	0	773	-11	936	-3	985	-1	888	2
Tecentriq	938	10	975	5	865	1	933	2	905	0
Actemra/RoActemra	647	21	687	13	618	-2	658	8	672	7
Xolair	570	3	575	7	496	10	614	11	627	12
Kadcyla	485	5	480	13	483	3	516	9	495	7
Evrysdi	360	41	354	22	356	7	482	42	408	13
Phesgo	300	61	303	58	388	70	411	52	445	55
Alecensa	368	7	376	7	355	4	411	10	385	7
Herceptin	383	-13	365	-14	364	-17	376	-4	323	-13
MabThera/Rituxan	378	-13	370	-15	351	-18	355	-15	317	-14
Avastin	373	-18	363	-15	324	-15	330	-18	289	-19
Activase/TNKase	282	-4	270	-1	296	4	297	-7	302	9
Polivy	252	144	232	74	250	81	263	34	304	24
Gazyva	213	22	196	12	213	16	232	15	225	8
Pulmozyme	104	-15	110	-6	112	-6	113	2	104	4
Mircera	120	27	108	4	96	0	77	-15	131	10
CellCept	94	-9	98	-8	94	0	103	9	86	-5

* Over 500%

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023
Ocrevus	1,146	10	1,192	8	1,180	5	1,231	6	1,229	9
Hemlibra	615	15	631	8	592	-1	639	3	675	12
Vabysmo	532	276	594	142	650	91	721	68	775	49
Perjeta	338	-6	235	-35	343	-7	351	-6	335	1
Tecentriq	476	4	465	-4	436	-9	462	-7	427	-8
Actemra/RoActemra	303	33	346	33	278	-1	317	13	354	19
Xolair	570	3	575	7	496	10	614	11	627	12
Kadcyla	182	-2	189	3	186	-1	195	3	193	8
Evrysdi	126	14	124	11	135	16	148	13	146	18
Phesgo	111	54	103	27	126	36	132	18	146	34
Alecensa	119	4	127	13	104	4	132	14	136	16
Herceptin	82	-21	73	-20	67	-22	71	-16	63	-22
MabThera/Rituxan	227	-19	226	-22	204	-21	218	-17	193	-14
Avastin	114	-19	114	-9	99	-22	100	-18	90	-20
Activase/TNKase	267	-5	253	-1	282	4	279	-9	289	11
Polivy	106	161	110	173	117	166	138	80	155	50
Gazyva	103	24	98	14	100	7	117	22	116	16
Pulmozyme	71	-19	74	-9	66	-15	75	-2	72	3
Mircera	-	-	-	-	-	-	-	-	-	-
CellCept	6	-34	8	-1	5	-34	7	-18	5	-9

* Over 500%

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023
Ocrevus	293	10	289	11	310	8	329	15	322	11
Hemlibra	218	22	208	8	231	17	237	12	222	3
Vabysmo	82	*	91	406	138	224	149	153	167	104
Perjeta	202	0	161	-21	171	-19	170	-12	161	-19
Tecentriq	230	22	217	2	210	12	219	8	220	-3
Actemra/RoActemra	200	11	192	-1	188	1	175	-8	145	-26
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	148	-6	131	-17	145	-2	143	0	140	-5
Evryydi	133	35	135	39	137	27	149	16	149	13
Phesgo	144	47	150	49	169	55	185	47	189	33
Alecensa	72	5	72	1	72	3	73	-1	72	0
Herceptin	88	-9	82	-10	77	-17	77	-12	73	-16
MabThera/Rituxan	44	-11	40	-15	39	-20	38	-14	32	-29
Avastin	21	-50	20	-43	21	-27	23	-14	19	-9
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Polivy	56	53	37	-21	54	42	32	-23	56	2
Gazyva	63	29	55	18	62	17	61	9	62	-1
Pulmozyme	18	-18	19	-15	20	0	19	3	16	-11
Mircera	11	-2	10	-2	10	-8	11	-7	10	-4
CellCept	31	-4	28	-14	32	0	28	-9	21	-30

* Over 500%

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023
Ocrevus	-	-	-	-	-	-	-	-	-	-
Hemlibra	89	5	92	5	79	2	92	4	88	4
Vabysmo	24	77	28	42	23	33	30	38	33	40
Perjeta	52	6	54	3	36	-19	30	-39	26	-48
Tecentriq	99	5	106	3	86	-4	96	0	95	0
Actemra/RoActemra	75	4	79	3	68	5	78	9	79	11
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	25	-15	25	-6	21	-4	25	8	25	7
Evrysdi	22	21	26	19	20	13	24	16	22	2
Phesgo	-	-	4	-	19	-	31	-	38	-
Alecensa	50	5	55	5	43	3	53	5	48	2
Herceptin	7	-35	6	-31	4	-41	4	-48	3	-56
MabThera/Rituxan	6	-11	5	-15	4	-20	5	-26	3	-30
Avastin	73	-28	68	-31	51	-33	51	-34	47	-32
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Polivy	59	178	60	55	44	2	48	-5	51	-9
Gazyva	8	-18	10	-4	6	-19	9	-14	6	-17
Pulmozyme	-	33	1	-4	-	27	-	24	1	2
Mircera	13	-22	13	-22	9	-25	10	-22	9	-23
CellCept	11	-15	11	-12	9	-10	9	-11	9	-7

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*

CHF millions	Q3 2023	% change vs. Q3 2022	Q4 2023	% change vs. Q4 2022	Q1 2024	% change vs. Q1 2023	Q2 2024	% change vs. Q2 2023	Q3 2024	% change vs. Q3 2023
Ocrevus	128	50	133	22	168	28	141	27	146	23
Hemlibra	103	39	104	14	138	51	135	16	152	64
Vabysmo	18	**	31	**	36	397	47	281	47	180
Perjeta	321	4	323	21	386	14	434	14	366	25
Tecentriq	133	18	187	39	133	34	156	30	163	32
Actemra/RoActemra	69	20	70	-3	84	-15	88	32	94	52
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	130	41	135	91	131	19	153	27	137	20
Evryssi	79	134	69	18	64	-29	161	169	91	8
Phesgo	45	151	46	196	74	165	63	75	72	87
Alecensa	127	10	122	5	136	5	153	15	129	4
Herceptin	206	-11	204	-12	216	-14	224	6	184	-6
MabThera/Rituxan	101	4	99	2	104	-11	94	-12	89	-7
Avastin	165	-5	161	-4	153	3	156	-11	133	-14
Activase/TNKase	15	-1	17	-1	14	7	18	25	13	-16
Polivy	31	422	25	214	35	181	45	72	42	42
Gazyva	39	18	33	2	45	47	45	14	41	7
Pulmozyme	15	14	16	18	26	22	19	17	15	32
Mircera	96	44	85	11	77	6	56	-15	112	16
CellCept	46	-6	51	-4	48	8	59	30	51	13

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

** Over 500%